XI’AN, China, Aug. 13 /Xinhua-PRNewswire-FirstCall/ -- Skystar Bio-Pharmaceutical Co., Ltd. (“Skystar” or the “Company”) today announced that it will conduct a conference call at 10:00 a.m. Eastern Time on Wednesday, August 15, 2007 to discuss the second quarter 2007 financial results.
Joining Mr. Weibing Lu, Chairman and Chief Executive Officer of Skystar, will be Ms. Erna Gao, Chief Financial Officer, Mr. Scott Cramer, Director and U.S. representative, and Mr. Wei Wen, Secretary and Director. The Company plans to make its earnings announcement earlier that same day.
To participate in the live conference call, please dial the following number five to ten minutes prior to the scheduled conference call time: 866- 202-3048. International callers should dial 617-213-8843. When prompted by the operator, mention Conference Passcode 60925366.
If you are unable to participate in the call at this time, a replay will be available for seven days starting on Wednesday, August 15 at 12:00 p.m. Eastern Time. To access the replay, dial 888-286-8010 and enter the passcode 14701349. International callers should dial 617-801-6888 and enter the same passcode 14701349.
In addition, the conference will be broadcast live over the Internet and can be accessed by all interested parties at http://phx.corporate-ir.net/playerlink.zhtml?c=197014&s=wm&e=1624298 . To listen to the call please go to the website at least 15 minutes prior to the start of the call to register, download and install any necessary audio software.
About Skystar Bio-Pharmaceutical
Skystar Bio-Pharmaceutical Company is a China-based producer and distributor of vaccines, microorganisms and veterinary medication to cure and prevent disease in poultry, livestock, birds and pets. The company’s product line consists of more than 100 products with over 50 additional products in the developmental stage. Skystar has formed strategic sales distribution networks throughout China. The company recently completed the first phase of construction of new state-of-the-art bio-pharmaceutical facilities covering an area of almost eight acres. The new facilities meet or exceed all Good Manufacturing Practice (GMP) Certification Standards and have received GMP Certification from the Chinese government. For additional information, please visit http://www.skystarbio-pharmaceutical.com .
Safe Harbor Statement
This announcement may contain “forward-looking statements” within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical fact in this announcement are forward-looking statements, including but not limited to, statements regarding the Company’s plans for future operations. These forward- looking statements involve known and unknown risks and uncertainties and are based on current expectations, assumptions, estimates and projections about the Company and the industry. Although the Company believes that the expectations expressed in these forward looking statements are reasonable, they cannot assure you that their expectations will turn out to be correct, and investors are cautioned that actual results may differ materially from the anticipated results.
For more information, please contact: Scott Cramer Director - U.S. Representative Skystar Bio-Pharmaceutical Co., Ltd Tel: +1-407-645-4433 Email: scramer@skystarbio-pharmaceutical.com CCG Elite Investor Relations Crocker Coulson, President Email: crocker.coulson@ccgir.com Leslie Richardson, Financial Writer CCG Elite Investor Relations Tel: +1-310-231-8600 x122 Email: leslie.richardson@ccgir.com
Skystar Bio-Pharmaceutical Co., Ltd.
CONTACT: Scott Cramer, Director - U.S. Representative of SkystarBio-Pharmaceutical Co., Ltd, +1-407-645-4433, or scramer@skystarbio-pharmaceutical.com; or Crocker Coulson, President of CCG Elite InvestorRelations, crocker.coulson@ccgir.com, or Leslie Richardson, FinancialWriter of CCG Elite Investor Relations, +1-310-231-8600 x122, orleslie.richardson@ccgir.com, both for Skystar
